What we know from the research is that most patients who stop taking a GLP-1 regain weight and lose the cardiometabolic health benefits
Large scale study evaluates the association between glucagon-like peptide-1 (GLP-1) receptor agonist use and smell and taste disturbances
The consequences of the cardiovascular disease-related reductions in CBF include accelerated reduction in frontal, parietal, and temporal grey matter volumes (Moroni et al., 2018), cognitive deficits (Jiang et al., 2023), and increased risk of ADRD (Iturria-Medina et al., 2016), particularly in regions vulnerable to early pathology (entorhinal cortex, hippocampus, inferior parietal cortex, inferior temporal cortex) (Mattsson et al., 2014)
Medical History and Physical Examination The first step is to ask about the persons health history
The finest and most powerful anti-aging, non-toxic skin care products for women and men